XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (0.7) $ 78.8
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 18.3 13.2
Non-cash interest expense (1.3) 0.1
Loss (gain) on disposition of assets (1.0) (0.1)
Share-based compensation expense 7.7 6.4
Deferred income taxes 2.7 4.7
Unrecognized tax benefits (2.6) 6.7
Change in fair value of contingent consideration (0.4) (73.2)
Changes in assets and liabilities:    
Prepaid expenses 1.8 3.2
Trade accounts receivable (3.3) (6.2)
Other receivables (0.3) 0.3
Inventory 3.5 3.3
Prepaid taxes (3.6) (8.9)
Accounts payable (8.4) 0.4
Accrued liabilities (4.4) (5.8)
Deferred revenue (0.2) 0.6
Net cash provided by operating activities 7.8 23.5
CASH FLOWS FROM INVESTING ACTIVITIES    
Capital expenditures (1.3) (1.6)
Acquisitions, net of cash acquired (279.6)  
Purchases of marketable investment securities (14.4) (31.5)
Proceeds from maturities and sales of marketable investment securities 16.3 17.9
Net cash used in investing activities (279.0) (15.2)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from common stock issued under share-based compensation plans 2.1 1.7
Net proceeds from revolving credit facility 290.0  
Repayment of revolving credit facility (40.0) (25.0)
Net cash provided by (used in) financing activities 252.1 (23.3)
Effect of foreign exchange rates on cash and cash equivalents 1.5 0.5
Net decrease in cash and cash equivalents (17.6) (14.5)
Cash and cash equivalents at beginning of the period 110.9 102.4
Cash and cash equivalents at end of the period $ 93.3 $ 87.9